Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins-1 and -3 and angiotensin II in a rat sponge model.

Hu DE, Hiley CR, Fan TP

British journal of pharmacology1 Feb 1996Cited by 44 (Europe PMC)

PMID8821547PMCIDPMC1909324DOI10.1111/j.1476-5381.1996.tb15225.xPepBankPUB-08821547

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In the rat sponge model, daily 1000 pmol VIP caused intense neovascularization.
In plain wordsIn rats, a high daily dose of VIP caused strong new blood vessel growth in implanted sponges.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseNeovascularization at 1000 pmol VIP
Study
ratn: not reported in source
rat sponge model
Outcome group
Angiogenesis · Cardiovascular
Studied dose
1000 pmol dailyAs given in this study (rat).
Source sentences
Summary
Daily doses of the vasodilator peptide, VIP (1000 pmol), caused intense neovascularization
2 context sentences(design, population, supporting numbers)
Summary · context
1 The angiogenic activity of four vasoactive peptides with a range of vasodilator and vasoconstrictor properties, i.e. vasoactive intestinal peptide (VIP), endothelin-1, endothelin-3 and angiotensin II, were investigated in a rat sponge model.
Summary · context
Neovascularization was assessed by the 133Xe clearance technique and confirmed by histological studies.
Report a problemFND-0882154701
02AnimalAnimal study (in vivo)Efficacy outcome
In the rat sponge model, a lower VIP dose of 10 pmol produced no apparent effect on neovascularization.
In plain wordsIn rats, a low daily dose of VIP caused no clear new blood vessel growth in implanted sponges.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeNeovascularization at 10 pmol VIP
Study
ratn: not reported in source
rat sponge model
Outcome group
Angiogenesis · Cardiovascular
Studied dose
10 pmol dailyAs given in this study (rat).
Source sentences
Summary
but a lower dose (10 pmol) produced no apparent effect.
2 context sentences(design, population, supporting numbers)
Summary · context
1 The angiogenic activity of four vasoactive peptides with a range of vasodilator and vasoconstrictor properties, i.e. vasoactive intestinal peptide (VIP), endothelin-1, endothelin-3 and angiotensin II, were investigated in a rat sponge model.
Summary · context
Neovascularization was assessed by the 133Xe clearance technique and confirmed by histological studies.
Report a problemFND-0882154702

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

03AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Efficacy outcome
In the rat sponge model, 10 pmol VIP given with a subthreshold dose of interleukin-1 alpha produced an angiogenic response similar to that of the higher VIP dose.
In plain wordsIn rats, a low VIP dose given together with interleukin-1 alpha caused new blood vessel growth similar to the high VIP dose.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseNeovascularization with low-dose VIP plus interleukin-1 alpha
Study
ratn: not reported in source
rat sponge model
Outcome group
Angiogenesis · Cardiovascular
Source sentences
Summary
However, the lower dose of VIP, when given with a subthreshold dose of interleukin-1 alpha (0.3 pmol), produced an angiogenic response similar to that seen with the higher dose of VIP.
2 context sentences(design, population, supporting numbers)
Summary · context
1 The angiogenic activity of four vasoactive peptides with a range of vasodilator and vasoconstrictor properties, i.e. vasoactive intestinal peptide (VIP), endothelin-1, endothelin-3 and angiotensin II, were investigated in a rat sponge model.
Summary · context
Neovascularization was assessed by the 133Xe clearance technique and confirmed by histological studies.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0882154703
04AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism
In the rat sponge model, the VIP receptor antagonist VIP (10-28) inhibited the neovascular response to VIP given with interleukin-1 alpha.
In plain wordsIn rats, a VIP receptor blocker reduced the new blood vessel growth caused by VIP with interleukin-1 alpha.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseInhibition of VIP plus interleukin-1 alpha response by VIP(10-28)
Study
ratn: not reported in source
rat sponge model
Outcome group
Angiogenesis · Cardiovascular
Source sentences
Summary
The neovascular response induced by co-administration of VIP and interleukin-1 alpha was inhibited by simultaneous administration of 100 pmol VIP (10-28), a specific VIP receptor antagonist.
2 context sentences(design, population, supporting numbers)
Summary · context
1 The angiogenic activity of four vasoactive peptides with a range of vasodilator and vasoconstrictor properties, i.e. vasoactive intestinal peptide (VIP), endothelin-1, endothelin-3 and angiotensin II, were investigated in a rat sponge model.
Summary · context
Neovascularization was assessed by the 133Xe clearance technique and confirmed by histological studies.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0882154704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.